Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.63 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16511748 | 0.94 | LTB4R (0.57) | FFAR1CYP4F2CYP4A11LTA4HNPC1 | |
| SCHEMBL12688084 | 0.91 | FFAR1 (0.65) | FFAR1CYP4F2CYP4A11LTA4HMEN1 | |
| SCHEMBL16499178 | 0.88 | CYP4F2 (0.57) | FFAR1CYP4F2CYP4A11NPC1RAB9A | |
| SCHEMBL1745250 | 0.88 | FFAR1 (0.72) | FFAR1LTA4HNPC1RAB9APPARG | |
| SCHEMBL9206351 | 0.87 | ALOX5 (0.56) | FFAR1CYP4F2CYP4A11LTA4HNPC1 | |
| SCHEMBL8427671 | 0.85 | CYP4F2 (0.70) | FFAR1CYP4F2CYP4A11KMT2AMAPT | |
| SCHEMBL9826020 | 0.84 | FFAR1 (0.67) | FFAR1LTA4HNPC1RAB9APPARG | |
| SCHEMBL392863 | 0.84 | ALOX5 (0.66) | FFAR1NPC1RAB9ALTB4RLTB4R2 | |
| SCHEMBL3105018 | 0.84 | LTA4H (0.52) | LTA4HNPC1RAB9APPARGMEN1 | |
| SCHEMBL3334872 | 0.84 | FFAR1 (0.76) | FFAR1CYP4F2CYP4A11LTA4HNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8758767-B2 | Antigens targeted by prevalent pathogennic T cells in type 1 diabetes and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-06-24 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | FFAR1 326/4885CYP4F2 2224/4885CYP4A11 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.